Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting
29 août 2022 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results
09 août 2022 08h00 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors
02 août 2022 07h30 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
26 juil. 2022 07h30 HE
|
Reneo Pharmaceuticals, Inc.
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects...
Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 juil. 2022 08h00 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
30 juin 2022 08h00 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results
10 mai 2022 16h05 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
23 mars 2022 16h05 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Senior Leadership Promotions
07 mars 2022 08h30 HE
|
Reneo Pharmaceuticals, Inc.
Michael P. Cruse appointed Chief Operating OfficerJennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals,...
Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference
02 févr. 2022 08h00 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...